港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

勁方醫藥-B

30.140

-1.220-3.89%

成交量：39.22萬

成交額：1,192.42萬

市值：111.52億

市盈率：-15.25

高：32.280

開：31.860

低：29.800

收：31.360

52周最高：50.200

52周最低：24.320

股本：3.70億

香港流通股本：3.38億

量比：0.44

換手率：0.12%

股息：- -

股息率：- -

每股收益(LYR):-1.976

淨資產收益率：--

總資產收益率：-30.27%

市淨率：-3.86

市盈率(LYR):-15.25

市銷率: 52.67

資料載入中...

總覽公司新聞資訊公告

BRIEF-中國勁方醫藥香港IPO擬籌15.8億港元，鎖定RTW、匯添富等基石投資者

新股招股 | 勁方醫藥今日起至9月16日招股，一手入場費4119.13港元

老虎资讯综合

勁方醫藥-B(02595)擬全球發售7760萬股引入RTW基金等基石投資者

勁方醫藥尋求在香港IPO孖展15.8億港元

勁方醫藥-B(02595.HK)9月11日起招股發售價將為每股20.39港元

勁方醫藥-B，通過港交所聆訊，或很快香港上市 | 未盈利生物科技公司.IPO上市

港澳IPO上市

港股IPO市場：年內募資超1300億，市場火熱難擋，新規則下的基公錨新變化

18A再擴容！勁方醫藥能否成為KRAS賽道破局者？

一圖解碼：勁方醫藥過聆訊！虧損大降83.5%藏玄機

勁方醫藥-B，通過港交所IPO聆訊，或很快香港上市

勁方醫藥上市聆訊獲通過擬於港交所主板上市

中国上市公司网

勁方醫藥通過港交所聆訊報告期內持續虧損

新股消息 | 勁方醫藥通過港交所聆訊報告期內持續虧損

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02595/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02595","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","market":"HK","secType":"STK","nameCN":"勁方醫藥-B","latestPrice":30.14,"timestamp":1763453297692,"preClose":31.36,"halted":0,"volume":392200,"delay":0,"floatShares":338000000,"shares":370000000,"eps":-1.976,"marketStatus":"未開盤","change":-1.22,"latestTime":"11-18 16:08:17","open":31.86,"high":32.28,"low":29.8,"amount":11924193,"amplitude":0.079082,"askPrice":30.14,"askSize":200,"bidPrice":30.02,"bidSize":800,"shortable":0,"etf":0,"ttmEps":-2.744,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1763515800000},"marketStatusCode":0,"adr":0,"listingDate":1758211200000,"exchange":"SEHK","adjPreClose":31.36,"openAndCloseTimeList":[[1763429400000,1763438400000],[1763442000000,1763452800000]],"volumeRatio":0.435401,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02595\",,,,,undefined,":{"symbol":"02595","floatShares":338000000,"roa":"-30.27%","roe":"--","lyrEps":-1.976,"volumeRatio":0.435401,"shares":370000000,"dividePrice":0,"high":32.28,"amplitude":0.079082,"preClose":31.36,"low":29.8,"week52Low":24.32,"pbRate":"-3.86","psRate":"52.67","week52High":50.2,"institutionHeld":0,"latestPrice":30.14,"committee":0.6,"eps":-1.976,"divideRate":0,"volume":392200,"delay":0,"ttmEps":-2.744,"open":31.86,"prevYearClose":20.39,"prevWeekClose":32,"prevMonthClose":27.32,"prevQuarterClose":40,"fiveDayClose":29.12,"twentyDayClose":31.38,"sixtyDayClose":20.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02595\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02595\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02595\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02595\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02595","date":"2025-11-17","current":-10.983965,"percent":0.421053,"low":-19.62221,"twenty":-18.517901,"median":-10.725216,"eighty":-9.953838,"high":-9.058573,"avg":-12.920101,"sd":3.785473,"marketCap":11614697516},"quantilePoints":[{"date":"2025-09-19","current":-19.62221,"twenty":-19.62221,"median":-19.62221,"eighty":-19.62221,"marketCap":14538840523},{"date":"2025-09-26","current":-17.850791,"twenty":-18.989349,"median":-18.569255,"eighty":-18.336187,"marketCap":13192012066},{"date":"2025-10-03","current":-19.06699,"twenty":-19.162092,"median":-18.845312,"eighty":-18.417026,"marketCap":14124431767},{"date":"2025-10-10","current":-11.809112,"twenty":-19.045684,"median":-18.645404,"eighty":-16.087956,"marketCap":11948785798},{"date":"2025-10-17","current":-10.861917,"twenty":-19.006201,"median":-18.336187,"eighty":-11.374297,"marketCap":10981832034},{"date":"2025-10-24","current":-9.567304,"twenty":-18.816504,"median":-12.899451,"eighty":-10.554523,"marketCap":9676444452},{"date":"2025-10-31","current":-9.989391,"twenty":-18.681528,"median":-11.762498,"eighty":-10.081819,"marketCap":10118416331},{"date":"2025-11-07","current":-9.878556,"twenty":-18.646705,"median":-10.725216,"eighty":-9.89625,"marketCap":9999899010},{"date":"2025-11-14","current":-11.674836,"twenty":-18.558233,"median":-10.712517,"eighty":-9.936062,"marketCap":11851732160},{"date":"2025-11-17","current":-11.456675,"twenty":-18.517901,"median":-10.725216,"eighty":-9.953838,"marketCap":11614697516}],"updateTime":1763454099717},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02595\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2566939726","title":"BRIEF-中國勁方醫藥香港IPO擬籌15.8億港元，鎖定RTW、匯添富等基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2566939726","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566939726?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 09:06","pubTimestamp":1757552761,"startTime":"0","endTime":"0","summary":"BRIEF-中国劲方医药香港IPO拟筹15.8亿港元，锁定RTW、汇添富等基石投资者路透香港9月11日 - 中国生物制药公司--劲方医药科技（上海）股份有限公司2595.HK：* 全球发售7,760万股H股，发售价每股20.39港元；9月11日开始香港公开发售，9月19日开始于联交所买卖* 公司成立于2017年，是一家生物制药公司，专注于肿瘤（涵盖多种实体瘤的不同治疗线）以及自体免疫和炎症性疾病领","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nL3S3UY02H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RTW.UK","02595"],"gpt_icon":0},{"id":"1119117190","title":"新股招股 | 勁方醫藥今日起至9月16日招股，一手入場費4119.13港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119117190","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119117190?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 07:31","pubTimestamp":1757547065,"startTime":"0","endTime":"0","summary":"$劲方医药-B$  发布公告，公司拟全球发售7760万股H股，中国香港发售股份776万股，国际发售股份6984万股；2025年9月11日至9月16日招股；发售价将为每股发售股份20.39港元，每手买卖单位为200股，中信证券为独家保荐人；预期股份将于2025年9月19日开始在联交所买卖。申购阶梯：每手200股，入场费4119.13港元。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/94259b8a9e267743f37f374ba43bd291","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/94259b8a9e267743f37f374ba43bd291"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"劲方医药今日起至9月16日招股，一手入场费4119.13港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02595"],"gpt_icon":0},{"id":"2566933455","title":"勁方醫藥-B(02595)擬全球發售7760萬股 引入RTW基金等基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2566933455","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566933455?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 07:30","pubTimestamp":1757547021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B 于2025年9月11日-9月16日招股，拟全球发售7760万股H股，香港公开发售占约10%，国际发售占约90%。据悉，该公司是一家具有全球视野、全球运营及国内外合作，并已有首创新药获批的新药开发公司。除RAS 外，该公司亦在探索自体免疫及炎症性疾病的治疗方案，包括公司的候选产品GFH312，以及其他癌症相关的疗法。假设发售量调整权或超额配股权未获行使及基于发售价为每股H股20.39港元，全球发售所得款项总净额约为14.436亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1343889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","02595","159938","BK1574","09939"],"gpt_icon":1},{"id":"2566933523","title":"勁方醫藥尋求在香港IPO孖展15.8億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566933523","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566933523?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 07:12","pubTimestamp":1757545940,"startTime":"0","endTime":"0","summary":"据在香港交易所的公告，劲方医药科技股份有限公司将在香港发行7760万股股份，发行价每股20.39港元；将融资15.8亿港元；股份将于9月19日开始挂牌交易。中信证券为独家保荐人。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/09/11071253062247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","BK1161","159938","09939","02595","BK1574"],"gpt_icon":0},{"id":"2566933558","title":"勁方醫藥-B(02595.HK)9月11日起招股 發售價將為每股20.39港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2566933558","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566933558?lang=zh_tw&edition=fundamental","pubTime":"2025-09-11 06:54","pubTimestamp":1757544879,"startTime":"0","endTime":"0","summary":"格隆汇9月11日丨劲方医药-B(02595.HK)发布公告，公司拟全球发售7760万股H股(视乎发售量调整权及超额配股权行使与否而定)，中国香港发售股份776万股，国际发售股份6984万股；2025年9月11日至9月16日招股；发售价将为每股发售股份20.39港元，每手买卖单位为200股，中信证券为独家保荐人；预期股份将于2025年9月19日开始在联交所买卖。\n\n\r\n            责任编辑：栎树","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/09/11065453062217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159938","BK1574","09939","BK1515","BK1161","02595"],"gpt_icon":0},{"id":"2565534400","title":"勁方醫藥-B，通過港交所聆訊，或很快香港上市 | 未盈利生物科技公司.IPO上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2565534400","media":"港澳IPO上市","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565534400?lang=zh_tw&edition=fundamental","pubTime":"2025-09-04 22:07","pubTimestamp":1756994820,"startTime":"0","endTime":"0","summary":null,"market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI1NTA3NDA2MA==&mid=2247504018&idx=2&sn=a6c1e00c7ce3c7253a92f1afd3d2a4d2&chksm=eb1821a306cbec6492b3d0d6be78eb2efb2a4932436cc1a39608411656ac1a9d9b1915e9f3be&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["02595"],"gpt_icon":0},{"id":"2564363280","title":"港股IPO市場：年內募資超1300億，市場火熱難擋，新規則下的基公錨新變化","url":"https://stock-news.laohu8.com/highlight/detail?id=2564363280","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564363280?lang=zh_tw&edition=fundamental","pubTime":"2025-09-03 08:16","pubTimestamp":1756858595,"startTime":"0","endTime":"0","summary":"2025年前8月，港股市场共有56只新股IPO上市，同比增长逾三成，累计募资达1333亿港元，同比增幅达573%，已达2023-2024年两年募资之和，继续领跑全球交易所IPO融资榜首。","market":"other","thumbnail":"https://images.finet.hk/photoLib/title/202509_1/ece0b45f-eee4-4af4-9e3f-d94180c1133c.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202509_1/ece0b45f-eee4-4af4-9e3f-d94180c1133c.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/68b788e45a77121f305b59f5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["02595","HSTECH","02525","BK4614","YANG"],"gpt_icon":1},{"id":"2564261820","title":"18A再擴容！勁方醫藥能否成為KRAS賽道破局者？","url":"https://stock-news.laohu8.com/highlight/detail?id=2564261820","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564261820?lang=zh_tw&edition=fundamental","pubTime":"2025-09-02 12:23","pubTimestamp":1756787005,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/K8EV120105568W0A.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/K8EV120105568W0A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["02595"],"gpt_icon":0},{"id":"2562829721","title":"一圖解碼：勁方醫藥過聆訊！虧損大降83.5%藏玄機","url":"https://stock-news.laohu8.com/highlight/detail?id=2562829721","media":"财华社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562829721?lang=zh_tw&edition=fundamental","pubTime":"2025-08-27 10:03","pubTimestamp":1756260228,"startTime":"0","endTime":"0","summary":"劲方医药通过港交所聆讯，8月25日就火速更新了聆讯后资料集，这次是中信证券独家保荐，距离挂牌上市只差临门一脚。这家2017年诞生的药企不简单：扎根中国，具有全球视野、全球运营及国内外合作，并已有首创新药获批的新药开发公司。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202508_1/f8a3d885-8f3a-4cee-b6ba-f88634a24165.jpg","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202508_1/f8a3d885-8f3a-4cee-b6ba-f88634a24165.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/68ae67845a7712326fcf9845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK1515","09939","BK1161","02595","BK1574"],"gpt_icon":0},{"id":"2562207914","title":"勁方醫藥-B，通過港交所IPO聆訊，或很快香港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2562207914","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562207914?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 13:56","pubTimestamp":1756187760,"startTime":"0","endTime":"0","summary":"　　2025年8月25日，劲方医药科技（上海）股份有限公司GenFleet Therapeutics  Inc．在港交所披露聆讯后的招股书，或很快在香港主板挂牌上市。　　劲方医药，于2025年6月25日获中国证监会国际司境外发行上市备案通知书，拟发行不超过102，633，800股境外上市普通股。　　截至最近，劲方医药已建立起1条持续更新的产品管线，包括8款候选药品，其中5款处于临床开发阶段。　　招股书显示，劲方医药在上市前的股东架构中，","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggipo/2025-08-26/doc-infnhvhi6797416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","HEXmain","159938","BK1574","09939","02595","BK1515"],"gpt_icon":0},{"id":"2562025942","title":"勁方醫藥上市聆訊獲通過 擬於港交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2562025942","media":"中国上市公司网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562025942?lang=zh_tw&edition=fundamental","pubTime":"2025-08-26 13:49","pubTimestamp":1756187340,"startTime":"0","endTime":"0","summary":"中国上市公司网讯 8月25日，劲方医药科技(上海)股份有限公司(以下简称“劲方医药”)上市聆讯获通过，公司将登陆港交所主板上市，独家保荐人为中信证券。公开数据显示，劲方医药成立于2017年 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250826/c670645220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02595","159938"],"gpt_icon":0},{"id":"2562242227","title":"勁方醫藥通過港交所聆訊 報告期內持續虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=2562242227","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562242227?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 21:18","pubTimestamp":1756127880,"startTime":"0","endTime":"0","summary":"据港交所8月25日披露，劲方医药科技(上海)股份有限公司(简称：劲方医药)通过港交所上市聆讯，中信证券为其独家保荐人。招股书显示，劲方医药是一家生物制药公司，专注于肿瘤(涵盖多种实体瘤 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250825/c670630336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["02595","159938"],"gpt_icon":0},{"id":"2562426002","title":"新股消息 | 勁方醫藥通過港交所聆訊 報告期內持續虧損","url":"https://stock-news.laohu8.com/highlight/detail?id=2562426002","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562426002?lang=zh_tw&edition=fundamental","pubTime":"2025-08-25 21:14","pubTimestamp":1756127690,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所8月25日披露，劲方医药科技(上海)股份有限公司通过港交所上市聆讯，中信证券为其独家保荐人。公司已在中国启动针对携带KRAS G12D突变的晚期实体瘤患者的I/II期临床试验的II期部分。KRAS G12D是最常见的致癌基因KRAS突变，尚无获批的治疗方案可用。财务方面，于2023年度、2024年度及2025年截至4月30日止四个月，劲方医药现收入分别约为7373.4万元、1.05亿元、8214.9万元人民币；年/期内亏损分别约为5.08亿元、6.78亿元、6662.4万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1334778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","02595","HEXmain","159938","09939","BK1161","BK1515"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":73,"code":"91000000","status":"200"}]}}